

## ***Cholestatic pruritis agents prior authorization of benefits form***

**Contains confidential patient information**

Complete form in its entirety and fax to: Prior authorization of benefits center at **844-474-3341**.

**1. Patient information**
**2. Physician information**

Patient name: _____ Patient ID #: _____ Patient DOB: _____ Date of Rx: _____ Patient phone #: _____ Patient email address: _____	Prescribing physician: _____ Physician address: _____ Physician phone #: _____ Physician fax #: _____ Physician specialty: _____ Physician DEA: _____ Physician NPI #: _____ Physician email address: _____
---	--

**3. Medication**
**4. Strength**
**5. Directions**
**6. Quantity per 30 days**

			Specify:
--	--	--	----------

**7. Diagnosis:**

**8. Approval criteria:** (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.)

<input type="checkbox"/> Yes <input type="checkbox"/> No	Is this a renewal request?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the client have a diagnosis of progressive familial intrahepatic cholestasis (PFIC) confirmed with genetic testing?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the client have a diagnosis of PFIC type 2 with ABCB11 variants resulting in non-functional or complete absence of bile salt export pump protein (BSEP3)?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the client have a history of liver transplant?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the client have a history of biliary diversion surgery in the last 180 days?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Has the client had at least 90 days therapy in the last 180 days of a standard agent used for the treatment of cholestatic pruritis (for instance, Cholestyramine, Naltrexone, Prevalite, Questran, Rifampin, Sertraline, Urso, Urso Forte, Ursodiol, Zolof)?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the client have an ALT and total bilirubin that is less than (<) 10 times the upper limit of normal (ULN)?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the client have a diagnosis of Alagille syndrome confirmed with genetic testing?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Will the client have concurrent therapy with another ileal bile acid transporter (IBAT) inhibitor?
For the <i>Medicaid Preferred Drug List</i> , please refer to the Medicaid Vendor Drug Program website at <a href="https://www.txvendordrug.com/formulary/formulary-search">https://www.txvendordrug.com/formulary/formulary-search</a>	

<https://provider.amerigroup.com/TX>

Amerigroup members in the Medicaid Rural Service Area and the STAR Kids program are served by Amerigroup Insurance Company; all other Amerigroup members in Texas are served by Amerigroup Texas, Inc.

## 9. Physician signature

\_\_\_\_\_  
Prescriber or authorized signature

\_\_\_\_\_  
Date

*Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate and complete and the requested services are medically indicated and necessary to the health of the patient. Note: Payment is subject to member eligibility. Authorization does not guarantee payment.*

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.